Genetics of neonatal cardiomyopathy

Current Opinion in Cardiology

Volumn 14, Issue 3, 1999, Pages 250-262

  Towbin, Jeffrey A ^a,c   Lipshultz, Steven E ^b  

^a TEXAS CHILDREN S HOSPITAL   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BECKWITH WIEDEMANN SYNDROME; CARDIOMYOPATHY; CLINICAL FEATURE; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FATTY ACID OXIDATION; GENETICS; GLYCOGEN STORAGE DISEASE TYPE 2; HEART DILATATION; HEART MITOCHONDRION; HEART TRANSPLANTATION; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; LABORATORY TEST; MORBIDITY; MORTALITY; NEWBORN; NEWBORN DISEASE; NOONAN SYNDROME; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SUDDEN DEATH; THORAX RADIOGRAPHY;

CARDIOMYOPATHIES; CARDIOMYOPATHY, DILATED; CARDIOMYOPATHY, HYPERTROPHIC; CHILD, PRESCHOOL; DNA, MITOCHONDRIAL; HUMANS; INFANT; INFANT, NEWBORN; MITOCHONDRIA, HEART;

EID: 0032950899     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001573-199905000-00010     Document Type: Review

References (80)

1. 1 Seidman CE, Seidman JG: Gene mutations that cause familial hypertrophic cardiomyopathy. In Molecular Cardiovascular Medicine. Edited by Haber E. New York: Scientific American Press, 1995:193-210.
2. 2 Maron BJ, TaJik AJ, Ruttenberg HD, Graham TP, Atwood GF, Vitbrica BE, Lie JJ, Roberts WC: Hypertrophic cardiomyopathy in infants: clinical features and natural history. Circulation 1982, 65:7-16.
3. 3 Kohlschutter A, Hausdor FG: Primary (genetic) cardiomyopathies in infancy: a survey of possible disorders and guidelines for diagnosis. Eur J Pediatr 1986, 145:454-459.
4. 4 Towbin JA, Roberts R: Cardiovascular diseases due to genetic abnormalities. In Hurst's The Heart, edn 9. Edited by Alexander RW, Schlant RC, Fuster V. New York: McGraw-Hill, 1998:1877-1924.
5. 5 Mott AR, Pac F, Denfield SW, Price JK, Belmont J, Craigen W, et al.: Hypertrophic cardiomyopathy in children. J Am Coll Cardiol 1999, in press.
6. 6 Towbin JA: Molecular genetic aspects of cardiomyopathy. Biochem Med Metab Biol 1993, 49:285-320.
7. 7 Richardson P, McKenna W, Bristow M, Maisch B, Mautner B, O'Connell J, et al.: Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of Cardiomyopathies: Circulation 1996, 93:841-842.
8. 8 Chin TK, Perloff JK, Williams RG, Jue K, Mohrmann R: Isolated noncompaction of left ventricular myocardium: a study of eight cases. Circulation 1990, 82:507-513.
9. 9 Noonan JA, Ehmke DA: Associated noncardiac malformations in children with congenital heart disease. J Pediatr 1963, 63:468-470.
10. 10 Allanson JE: Noonan syndrome. J Med Genet 1987, 4:9-13.
11. 11 Sharland M, Burch M, McKenna WM, Paton MA: A clinical study of Noonan syndrome. Arch Dis Child 1992, 67:178-183.
12. 12 Van der Hauwaert LG, Fryns JM, Dumoulin M, Logghe N: Cardiovascular malformations in Turner's and Noonan's syndrome. Br Heart J 1978, 40:500-509.
13. 13 Towbin JA, Greenberg F: Genetic syndromes and genetics. In Science and Practice of Pediatric Cardiology. Edited by Bricker JT, Garson A Jr, Fisher DJ. Philadelphia: Williams & Wilkins, 1998: 2627-2700.
14. 14 Jamieson CR, van der Burgt I, Brandy AF, van Reen, M, Elsawi MM, Hol F. et al.: Mapping a gene for Noonan syndrome to the long arm of chromosome 12. Nat Genet 1994, 8:357-360.
15. 15 Best LG, Hoekstra RE: Wiedemann-Beckwith syndrome: autosomal dominant inheritance in a family. Am J Med Genet 1981, 9:291-299.
16. 16 Lee MP, Hu RJ, Johnson LA, Feinberg AP: Human KVLQT1 gene shows tissue-specific imprinting and encompasses Beckwith-Wiedemann syndrome chromosomal rearrangements. Nat Genet 1997, 15:181-185.
17. 17 Rauser AJ, Kroos MA, Hermans MM, Bijvoet AG, Verbeet MP, Van Diggelen OP, et al.: Glycogenosis type II (acid maltase deficiency). Muscle Nerve 1995, 3:861-869.
18. 18 Raben N, Nichols RC, Boerkoel C, Plotz P: Genetic defects in patients with glycogenosis Type II (acid maltase deficiency). Muscle Nerve 1995. 3:870-874.
19. 19 Bijvoet AGA, van de Kamp EHM, Kroos MA, Ding J-H, Yang BZ, Visser P, et al.: Generalized glycogen storage and cardiomegaly in a knockout mouse model of Pompe disease. Hum Mol Genet 1998, 7:53-62. A knockout mouse model of Pompe disease is reported. The authors identify the clinical features of this animal model.
20. 20 Pierpont MEM: Carnitine and myocardial function. In Current Concepts in Carnitine Research. Edited by Carter AL. Boca Raton: CRC Press, 1992:197-212.
21. 21 Strauss AW: Defects of mitochondrial proteins and pediatric heart disease. Prog Pediatr Cardiol 1996, 6:83-90.
22. 22 Kelly DP, Strauss AW: Inherited cardiomyopathies. N Engl J Med 1994, 13:913-919.
23. 23 Stanley CA, DeLeeuw S, Coates PM, Vianey-Liaud C, Divry P, Bonnefont J-P, et al.: Chronic cardiomyopathy and weakness or acute coma in children with a defect in carnitine uptake. Ann Neurol 1991, 30:709-716.
24. 24 Bennett MJ, Hale DE, Pollitt RJ, Stanley CA, Variend S: Endocardial fibro-elastosis and primary carnitine deficiency due to a defect in the plasma membrane carnitine transporter. Clin Cardiol 1996, 19:243-246.
25. 25 Waber LJ, Valle D, Neill C, DiMauro S, Shug A: Carnitine deficiency presenting as familial cardiomyopathy: a treatable defect in carnitine transport. J Pediatr 1982, 101:700-705.
26. 36 Shoji Y, Koizumi A, Kayo T, Ohata T, Takahashi T, Harada K, Takada G: Evidence for linkage of human primary systemic carnitine deficiency with D5S436: a novel gene locus on chromosome 5q. Am J Hum Genet 1998, 63:101-108. Identification of linkage to chromosome 5q31 for the gene responsible for primary carnitine deficiency. The authors also confirm synteny to mouse chromosome 11.
27. 27 Nikaido H, Horiuchi M, Hashimoto M, Sahek T, Hayakawa J: Mapping of JVS (juvenile visceral steatosis) gene, which causes systemic carnitine deficiency in mice, on chromosome 11. Mamm Genome 1995, 6:369-370.
28. 28 Nezu J-i, Tamai I, Oku A, Ohashi R, Yabuuchi H, Hashimoto N, et al: A primary systemic carnitine deficiency is caused by mutations in a gene encoding sodium ion-dependent carnitine transporter. Nat Genet 1999, 21:91-94. Mutations in OCTN2, a gene localized to 5q31, is shown to cause primary systemic carnitine deficiency. Abnormalities in this sodium ion-dependent carnitine transporter results in complete clinical syndrome including cardiomyopathy.
29. 29 Taroni F: Carnitine palmitoyl transferase deficiency. In. Edited by Gilman S, Goldstein GW, Waxman SG. La Jolla: Arbor Publishing, 1995.
30. 30 Britton CH, Schultz RA, Zhang Z, Esser V, Foster DW, McGarry JD: Human liver mitochondrial CPT-1. Proc Natl Acad Sci U S A 1995, 52:1984-1988.
31. 31 Hug G, Bove KE, Soukup S: Lethal neonatal multiorgan deficiency of CPT-II. N Engl J Med 1991, 325:1862-1865.
32. 32 Demaugre F, Bonnefont J-P, Colonna M, Cepanec C, Laroux J-P, Saudubray J-M: Infantile CPT-II deficiency with hepato-muscular symptoms and sudden death. J Clin Invest 1991, 87:859-864.
33. 33 Kelly KP, Kim J, Billadello JJ, Hainline BE, Chu TW, Strauss AW: Nucleotide sequence of medium-chain acyl-CoA dehydrogenase mRNA and its expression in enzyme-deficient human tissue. Proc Natl Acad Sci U S A 1987, 84:4068-4072.
34. 34 Halo DE, Batshaw ML, Coates PM, Frerman FE, Goodman SI, Singh I, Stanley CA: Long chain acyl-CoA dehydrogenase deficiency: An inherited cause of nonketotic hypoglycemia. Pediatr Res 1985, 19:666-671.
35. 35 Strauss AW, Powell CK, Hale DF, Anderson MM, Ahuja A, Brackett JC, Sims HF: Molecular basis of human mitochondrial VLCAD deficiency causing cardiomyopathy and sudden death in childhood. Proc Natl Acad Sci U S A 1995, 92:10496-10500.
36. 36 Andresen BS, Bross P, Vianey-Saban C, Divry P, Zabot MT, Roe CR, et al.: Cloning and characterization of human VLCAD, chromosomal assignment of the gene and identification of four patients with nine different mutations within the VLCAD gene. Hum Mol Genet 1996, 5:461-472.
37. 37 Wanders RJA, Duran M, Ijst L, de Jager JP: Sudden infant death and LCHAD. Lancet 1989, 2:52-53.
38. 38 Ijlst L, Wanders RJA, Ushikubo S, Kimijo T, Hashimoto T: Molecular basis of LCHAD deficiency: identification of the major disease-causing mutation in the β-subunit of the mitochondrial trifunctional protein. Biochem Biophys Acta 1994, 215:347-350.
39. 39 Sims HF, Brackett JC, Powell CK, Treem WR, Hale DE, Bennett MJ, et al.: The molecular basis of pediatric LCHAD deficiency associated with maternal acute fatty liver of pregnancy. Proc Natl Acad Sci U S A 1995, 92:841-845.
40. 40 Wallace DC: Diseases of the mitochondrial DNA. Annu Rev Biochem 1992, 61:175-1212.
41. 41 Attardi G: The elucidation of the human mitochondrial genome: a historical perspective. Bioessays 1994, 5:34-39.
42. 42 Lightowlers RN, Chinnery PF, Turnbull DM, Howell N: Mammalian mitochondrial genetics: heredity, heteroplasmy and disease. Trends Genet 1997, 13:450-455. An excellent review of mitochondrial genetics and mitochondrial disease.
43. (UUR) mutation associated with maternally inherited myopathy and cardiomyopathy. J Clin Invest 1994, 93:1102-1107.
44. 44 Wallace DC, Zheng X, Lott MT, Shoffner JM, Hodge JA, Kelley R et al.: Familial mitochondrial encophalomyopathy (MERRF): genetic, pathophysiological, and biochemical characterization of a mitochondrial DNA disease. Cell 1988, 55:601-610.
45. 45 Marin-Garcia J, Goldenthal MJ: Mitochondrial cardiomyopathy: molecular and biochemical analysis. Pediatr Cardiol 1997, 18:251-260.
46. 46 Shoffner JM, Wallace DC: Heart disease and mitchondrial DNA mutations. Heart Dis Stroke 1992, 235-241.
47. 47 Larsson NG, Clayton DA: Molecular genetic aspects of human mitochondrial disorders. Annu Rev Genet 1995, 29:151-178.
48. 48 Kobayashi M, Morishita H, Sugiyama N, Yokochi K, Nakano A, Wada Y, et al.: Two cases of NADH-coenzyme Q reductase deficiency. Relationship to MELAS syndrome. J Pediatr 1987, 110:223-227.
49. 49 Tanaka, Ino H, Ohno K, Hattori K, Sato W, Ozawa T, et al.: Mitochondrial mutation in fatal infantile cardiomyopathy. Lancet 1960, 1:1452.
50. 50 Brown MD, Voljavec AS, Lott MT, Torroni A, Yang CC, Wallace DC: Mitochondrial DNA complex I and III mutations associated with Leber's hereditary optic neuropathy. Genetics 1992, 130:163-173.
51. 51 Papadimitriou A, Neustein HB, DiMauro S, Stanton R, Bresolin N: Histiocytoid cardiomyopathy of infancy: deficiency of reducible cytochrome b in heart mitochondria. Pediatr Res 1984, 18:1023-1028.
52. 52 DiMauro S, Nicholoson JF, Hays AP, Eastwood AB, Papadimitriou A, Koenigsberger R, et al.: Benign infantile mitochondrial myopathy due to reversible cytochrome C oxidase deficiency. Ann Neurol 1983, 14:226-234.
53. 53 Sevidei S, Bertini E, Manfredi G, Dionnisi Vici C, Silvestri G, Ricci E, et al.: Familial infantile myopathy and cardiomyopathy with deficiency of cytochrome c oxidase and mitochondrial adenosine triphosphate synthase. Ann Neurol 1993, 34:463-464.
54. 54 Bergelson JM, Cunningham JA, Droguett HG, Kurt-Jones EA, Krithvas A, Hong JS, et al.: Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 1997, 275:1230-1323. The isolation of a cDNA clone that encodes the common receptor for the coxsackievirus B and adenovirus (subgroup C) families is described.
55. 55 Morgan-Hughes JA, Sweeney MG, Cooper JM, Hammans SR, Brockington M, Schapira AH, et al,: Mitochondrial DNA (mtDNA) diseases: correlation of genotype to phenotype. Biochem Biophys Acta 1995, 1271:135-140.
56. 56 Shoffner JM, Lott MI, Lezza AMS, Seibel P, Balliner SW, Wallace DC: Myotonic epilepsy and ragged-red fiber disease (MERRF) is associated with a mitochondrial DNA tRNALYS mutation. Cell 1990, 61:931-937.
57. 57 Pavalakis SG, Phillips PC, DiMauro S, DeVivo DC, Rowland LP: Mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes: a distinctive clinical syndrome. Ann Neurol 1984, 16:481-487.
58. 58 Graham BH, Waymire KG, Cottrell B, Trounce IA, MacGregor GR, Wallace DC: A mouse model for mitochondrial myopathy and cardiomyopathy resulting from a deficiency in the heart/muscle isoform of the adenine nucleotide translocator. Nat Genet 1997, 16:226-234. The authors generated knockout mice deficiency in the heart/muscle isoform of the adenine nucleotide translocator, adenine nucleotide translocator 1. Histologic and ultrastructural examination demonstrate mitochondrial proliferation and ragged red fibers in skeletal muscle and cardiac hypertrophy with mitochondrial proliferation.
59. 59 Ferencz C, Neill CA: Cardiomyopathy in infancy observations in an epidemiologic study. Pediatr Cardiol 1992, 13:65-71.
60. 60 Manolio TA, Baughman KL, Rodeheffer R, Pearson TA, Bristow JD, Michels W, et al.: Prevalence and etiology of idiopathic dilated cardiomyopathy (summary of a National Heart, Lung, and Blood Institute Workshop). Am J Cardiol 1992, 69:1458-1466.
61. 61 Codd MB, Sugrue DD, Gersh BJ, Melton LJ III: Epidemiology of idiopathic dilated and hypertrophic cardiomyopathy: a population-based study in Olmsted County, Minnesota, 1975-1984. Circulation 1989, 80:564-572.
62. 62 Matitiau A, Perez-Atayde A, Sanders SP, Sluysman T, Parness IA, Spevak PJ, Colon SD: Infantile dilated cardiomyopathy: relation of outcome to left ventricular mechanics, hemodynamic, and histology at the time of presentation. Circulation 1994, 90:1310-1318.
63. 63 Friedman RA, Schowengerdt KO, Towbin JA: In Science and Practice of Pediatric Cardiology. Edited by Bricker JT, Garson A Jr, Fisher DJ. Philadelphia: Williams & Wilkins, 1998; 79:1777-1794.
64. 64 Tomko RP, Xu R, Philpson L: HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxasackieviruses. Proc Natl Acad Sci U S A 1997, 94:3352-3356. The authors characterize the common receptor for coxsackievirus B and adenovirus from human and mouse cells, demonstrating it to be part of the immunoglobulin-like receptor super family.
65. 65 Neustein HB, Lurie PR, Dahms B, Takahashi M: An X-linked recesive cardiomyopathy with abnomal mitochondria. Pediatrics 1979, 64: 24-29.
66. 66 Barth PG, Scholte HR, Berden JA, Van Der Kloi-Van Moorsel JM, Luyt-Houwen IEM, Van'T Vur-Korthof ET, et al.: An X-linked mitochondrial disease affecting cardiac muscle, skeletal muscle and neutrophil leukocytes. J Neurol Sci 1983, 62:337-355.
67. 67 Kelley RI, Cheatham JP, Clark BJ, Nigro MA, Powell BR, Sherwood GW, et al.: X-linked dilated cardiomyopathy with neutropenia, growth retardation, and 3-methylglutaconic aciduria. J Pediatr 1991, 119: 738-747.
68. 68 Bolhuis PA, Hansels GW, Hulsebos TJM, Baas F, Barth PG: Mapping of the locus for X-linked cardioskeletal myopathy with neutropenia and abnormal mitochondria (Barth syndrome) to Xq28. Am J Hum Genet 1991, 48:481-485.
69. 69 Bione S, D'Adamo P, Maestrini E, Gedeon AK, Bolhuis PA, Toniolo D: A novel X-linked gene G4.5 is responsible for Barth syndrome. Nat Genet 1996, 12:385-389.
70. 70 Johnson J, Kelley RI, Feigenbaum A, Cox GF, Iyer GS, Funage VL, Proujansky R: Mutation characterization of genotype phenotype correlation in Barth syndrome. Am J Hum Genet 1997, 61:1053-1058. Fourteen families with Barth syndrome were screened for mutations; unique mutations were found in all families. Although exons 3 and 8 are apparent mutation "hot spots", no correlation between genotype and phenotype was found.
71. 71 D'Adamo P, Fassone L, Gedeon A, Janssen EAM, Bione S, Bolhuis PA, et al.: The X-linked gene G4,5 is responsible for different infantile dilated cardiomyopathies. Am J Hum Genet 1997, 61 :862-867. The authors show that mutations in G4,5 result in Barth syndrome, X-linked EFE, and severe X-linked cardiomyopathy (X-linked fatal cardiomyopathy).
72. 72 Gedeon AK, Wilson MJ, Colley AC, Sillence DO, Mulley JC: X-linked fatal cardiomyopathy maps to Xq28 and is possibly allelic to Barth syndrome. J Med Genet 1995, 32:383-388.
73. 73 Bleyl SB, Mumford BR, Thompson V, Carey JC, Pysher TJ, Chin TJ, Ward K: Neonatal lethal noncompaction of the left ventricular myocardium is allelic with Barth syndrome. Am J Hum Genet 1997, 61:868-872.
74. 74 Orstavik KH. Orstavik RE, Naumova AK, D'Adamo P, Gedeon A, Bolhuis PA, et al.: X chromosome inactivation in carriers of Barth syndrome. Am J Hum Genet 1998, 63:1457-1463. The authors provide evidence that female carriers remain clincally unaffected because of inactivation of the X chromosome.
75. 75 Kearns TP, Sayre GP: Retinitis pigmentosa, external ophthalmoplegia, and complete heart block. Arch Ophthalmol 1958, 60:280-289.
76. 76 Channer KS, Channer JL, Campbell MJ, Rees JR: Cardiomyopathy in Kearns-Sayre syndrome. Br Heart J 1988, 59:486-490.
77. 77 Zeviani M, Moraes CT, DiMauro S, Nakase H, Bonilla E, Schon EA, Rowland LP: Deletions of mitochondrial DNA in Kearns-Sayre syndrome. Neurology 1998, 38:1339-1346.
78. 78 Remes A, Hassinen IE, Ikaheimo MJ, Herva R, Hirvonen J, Peuhkurinen KJ: Mitochondrial DNA deletions in dilated cardiomyopathy: clinical study employing endomyocardial sampling. J Am Coll Cardiol 1994, 23:935-942.
79. 79 Wang J, Wilhelmsson H, Graff C, Li H, Oldfors A, Rustin P, et al.: Dilated cardiomyopathy and atrioventricular conduction blocks induced by heart-specific inactivation of mitochondrial DNA gene expression. Nat Genet 1999, 21:133-137. Using a loxP-flanked Tfam allele in combination with a cre-recombinase transgene under control of muscle creatine kinase promoter, the authors disrupted the gene encoding mitochondrial transcription factor A in heart and muscle of mice. This results in clinicical Kearns-Sayre syndrome in these animals.
80. 80 Larsson N-G, Wang J, Wilhelmsson H, Oldfors A, Rustin P. Lewandoski M, et al.: Mitochondrial transcription factor A is necessary for mtDNA maintenance and embryogenesis in mice. Nat Genet 1998, 18: 231-236. Knockout mice produced with mutant mitochondrial transcription factor A, which regulates expression of mtDNA. The heart was shown to be most sensitive to reduction in Tfam.